Abstract
Objectives This study investigated the potential of testing for active matrix metalloproteinase-8
(aMMP-8) by a quantitative point-of-care (PoC), chairside, lateral flow immunotest
as a biomarker for the presence or absence of peri-implant diseases.
Materials and Methods Eighty healthy patients with implants were recruited. The samples were collected
from peri-implant sulcular fluid and quantitatively analyzed for aMMP-8. Clinical
indices, which included probing depth, clinical attachment loss, bleeding on probing,
and plaque, were recorded and radiographic assessments were performed.
Statistical Analysis Comparisons of aMMP-8 levels and clinical parameters were analyzed by the Kruskal–Wallis
test and the pairwise post hoc Dunn–Bonferroni test. A receiver operating curve analysis
was used to analyze the diagnostic ability of aMMP-8 and the correlation between aMMP-8
and probing depth of the sampled site was sought by Spearman's rho and the coefficient
of determination (R
2).
Results Statistical analysis revealed statistically significant differences of aMMP-8 levels
between the healthy and the mucositis and peri-implantitis groups, and between the
mucositis and the peri-implantitis groups. Increasing probing depths of the sampled
site and aMMP-8 levels were significantly correlated.
Conclusions These data suggest that the aMMP-8 PoC test can be a beneficial adjunctive tool for
early identification and screening of the risk of peri-implant diseases and progression.
Keywords
aMMP-8 - peri-implant health - peri-implant disease
